Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 213, Issue 12, Pages 2527-2538Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20161596
Keywords
-
Categories
Funding
- European Research Council [GA 309449]
- ERA-NET Neuron [MR/M501803/1]
- MRC [MR/M501803/1] Funding Source: UKRI
- Medical Research Council [MR/M501803/1] Funding Source: researchfish
Ask authors/readers for more resources
Type I interferon is a potent substance. As such, the induction, transmission, and resolution of the type I interferon-mediated immune response are tightly regulated. As defined, the type I interferonopathies represent discrete examples of a disturbance of the homeostatic control of this system caused by Mendelian mutations. Considering the complexity of the interferon response, the identification of further monogenic diseases belonging to this disease grouping seems likely, with the recognition of type I interferonopathies becoming of increasing clinical importance as treatment options are developed based on an understanding of disease pathology and innate immune signaling. Definition of the type I interferonopathies indicates that autoinflammation can be both interferon and noninterferon related, and that a primary disturbance of the innate immune system can spill over into autoimmunity in some cases. Indeed, that several non-Mendelian disorders, most particularly systemic lupus erythematosus and dermatomyositis, are also characterized by an up-regulation of type I interferon signaling suggests the possibility that insights derived from this work will have relevance to a broader field of clinical medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available